New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 6, 2013
15:32 EDTPGNXProgenics completes enrollment in Phase II prostate cancer trial
Progenics Pharmaceuticals announced that it has completed enrollment of chemotherapy experienced patients in a Phase II trial to assess the anti-tumor activity and tolerability of its antibody drug conjugate, PSMA ADC in patients with metastatic castrate resistant prostate cancer. A total of 83 patients who had progressive disease despite treatment with at least one taxane containing chemotherapy received PSMA ADC.
News For PGNX From The Last 14 Days
Check below for free stories on PGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PGNX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use